Lexicon Pharmaceuticals | LXRX - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Abbott USD 2.13B 281M 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Illumina USD 260M 21M 2026-06
Insmed USD -101.31M 98.97M 2026-06
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
J&J USD 7.48B 860M 2026-06
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
MacroGenics USD -33.44M 21.34M 2026-03
MannKind USD -68.23M 8.76M 2026-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Novartis USD 4.75B 515M 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Thermo Fisher Scientific USD 2.18B 273M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12